Elsevier

Neurobiology of Aging

Volume 35, Issue 2, February 2014, Pages 271-278
Neurobiology of Aging

Regular article
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease

https://doi.org/10.1016/j.neurobiolaging.2013.08.001Get rights and content

Abstract

Abberant lipid metabolism is implicated in Alzheimer's disease (AD) pathophysiology, but the connections between AD and lipid metabolic pathways are not fully understood. To investigate plasma lipids in AD, a multiplatform screen (n = 35 by liquid chromatography–mass spectrometry and n = 35 by nuclear magnetic resonance) was developed, which enabled the comprehensive analysis of plasma from 3 groups (individuals with AD, individuals with mild cognitive impairment (MCI), and age-matched controls). This screen identified 3 phosphatidylcholine (PC) molecules that were significantly diminished in AD cases. In a subsequent validation study (n = 141), PC variation in a bigger sample set was investigated, and the same 3 PCs were found to be significantly lower in AD patients: PC 16:0/20:5 (p < 0.001), 16:0/22:6 (p < 0.05), and 18:0/22:6 (p < 0.01). A receiver operating characteristic (ROC) analysis of the PCs, combined with apolipoprotein E (ApoE) data, produced an area under the curve predictive value of 0.828. Confirmatory investigations into the background biochemistry indiciated no significant change in plasma levels of 3 additional PCs of similar structure, total choline containing compounds or total plasma omega fatty acids, adding to the evidence that specific PCs play a role in AD pathology.

Introduction

It is estimated that there are 24 million persons worldwide with Alzheimer's disease (AD), a figure that is expected to double every 20 years until at least 2040 (Mayeux and Stern, 2012). The size of the affected population and the nature of the disease poses a huge challenge to patient health and care organizations around the world. However, the full physiological mechanism of AD is yet to be fully elucidated, and there is thus a need to identify both disease-relevant pathways for targeted treatment as well as molecular markers to aid in clinical diagnosis and monitoring disease progression (Jack et al., 2011).

Previous research has indicated that lipid molecules play a role in AD, and these have frequently been reported at abnormal concentrations in AD tissue (Bradley et al., 2012, Mangialasche et al., 2012, Wang et al., 2012). Many of these prior studies were conducted using a targeted experimental design, in which known pathways of disease were investigated in a focused manner, based on previous hypotheses of disease pathogenesis. Such targeted approaches have provided evidence suggesting a link between AD and high-density lipoproteins (HDLs) and related proteins in plasma (Di Paolo and Kim, 2011, Han et al., 2011, Lovestone et al., 1996, Orešič et al., 2011, Thambisetty et al., 2010, Whiley and Legido-Quigley, 2011). In addition, the lipoproteins apolioprotein E (ApoE) and apolipoprotein J (ApoJ) have been linked to AD via both genetic and proteomic studies (Shi et al., 2012, Thambisetty et al., 2010). ApoJ has been found as a component of HDL and is thought to be a chaperone of amyloid protein, a protein known to be heavily involved in the pathology of AD (Hye et al., 2006, Thambisetty et al., 2010).

An alternative to such targeted discovery is the use of non-targeted small-molecule analysis, commonly termed metabolomics. In contrast to targeted studies, metabolomics attempts to analyze an expansive range of lipids and small metabolites. In metabolomics studies, small-molecule (size <1000–1500 Da) fingerprints are collected, and subsequent data mining can provide unexpected leads into the biochemistry of the disease. The range of molecules studied depends on the analytical platform used and on the applied methodology, with certain combinations of techniques achieving higher specificities (Martin et al., 2007, Whiley et al., 2012).

Non-targeted analysis of AD has previously been reported (Greenberg et al., 2009, Han et al., 2011, Orešič et al., 2011). The majority of these previous studies focus on plasma samples, analyzed either by liquid chromatography–mass spectrometry (LC-MS) (Greenberg et al., 2009, Orešič et al., 2011) or direct infusion mass spectrometry (DIMS) (Han et al., 2011). Interestingly, the significant molecular features identified in these previous works were lipid molecules. One of these studies reported an increase in ceramide (CM16) levels and a decrease in sphingolipid (SP16) levels in the plasma of AD patients (Han et al., 2011). Another investigation identified a phosphatidylcholine (PC), PC 16:0/16:0, as 1 of a cluster of 3 metabolites thought to be predictive markers of AD development in individuals with mild cognitive impairment (MCI) (Orešič et al., 2011). The third example reported a number of bile acids (GCA, GDCA, and GCDCA) that increase in MCI and AD plasma (Greenberg et al., 2009). The latter publication went on to recommend further investigation into the lipid fraction of the AD metabolome.

With these previous results in mind, we developed a non-targeted lipidomics to investigate plasma lipid species in AD. In the study described here, an initial metabolite screen involving LC-MS and nuclear magnetic resonance (NMR) profiling was performed, and the resultant data were analyzed using multivariate statistical modeling. The results of this “screen” phase indicated that 3 lipid phosphatidylcholine molecules (PC16:0/20:5, PC16:0/22:6, and 18:0/22:6) significantly decrease in AD plasma compared to controls. We then performed a multiplatform “validation”, designed to both confirm the findings, as well as provide further biological reasoning regarding the changes observed. Fig. 1 illustrates the overall study design and the individual analytical stages incorporated into each phase (screen and validation).

Section snippets

Sample cohorts

Plasma for the 2 experimental phases (screen and validation) was collected from 2 clinical cohorts, the AddNeuroMed cohort and the King's College London Dementia Case Register (DCR). Ethical approval was awarded for all cohorts in the corresponding centers of collection. The cohorts are described in full in the Supplementary Information section and are summarized in Supplementary Table S1. Further details regarding sample collection and the AddNueroMed and DCR cohorts can be found elsewhere (

Screen results

The initial phase of the study was divided into 2 experiments, incorporating both LC-MS and NMR technologies. LC-MS and NMR analysis was performed on 2 separate sample sets each consisting of 35 age- and sex-matched samples (Supplementary Table S1). After this, multivariate data modeling was completed, including principal component analysis (PCA) and OPLS-DA. Models created from the NMR data revealed no significant metabolite changes attributable to disease type.

LC-MS modeling (Fig. 2B)

Discussion

Here we report a significant reduction of 3 PC species in patients with AD compared with controls, which have not previously been linked to AD (PC16:0/20:5 (p < 0.001), PC16:0/22:6 (p < 0.05), and PC18:0/22:6 p < 0.005). The reduction was observed in 2 different sample sets, using 2 different LC-MS methods (in the screen and validation phases). In the validation result, the overall trend (i.e., control>MCI>AD) suggested a specific PC decline linked to cognition. Three PC species (PC16:0/20:4,

Disclosure statement

The authors declare no conflicts of interest is assotiated with this manuscript.

Acknowledgements

Supported by the UK NHS National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) for mental health at the South London and Maudsley (SLaM), the European Commision (AddNeuroMed) and the Waters Centre of Excellence for Mass Spectrometry at King's College London. All authors have reviewed and contributed to the writing of this manuscript.

References (49)

  • D.C. Wang et al.

    Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease

    Neurobiol. Aging

    (2012)
  • Y.Y. Zhao et al.

    Measurement of phospholipids by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry: the determination of choline containing compounds in foods

    J. Chromatogr. A

    (2011)
  • J.W. Ashford

    APOE genotype effects on Alzheimer's disease onset and epidemiology

    J. Mol. Neurosci.

    (2004)
  • M.C. Biagioni et al.

    Using biomarkers to improve detection of Alzheimer's disease

    Neurodegener. Dis. Manag.

    (2011)
  • J. Carrola et al.

    Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine

    J. Proteome Res.

    (2011)
  • V. Colangelo et al.

    Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling

    J. Neurosci. Res.

    (2002)
  • The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association, National Institute of Aging

    Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer's Disease”

    Neurobiol. Aging

    (1998)
  • P.E. Cramer et al.

    ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models

    Science

    (2012)
  • E.A. Dennis et al.

    Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention

    Chem. Rev.

    (2011)
  • G. Di Paolo et al.

    Linking lipids to Alzheimer's disease: cholesterol and beyond

    Nature. Rev. Neurosci.

    (2011)
  • I.F. Duarte et al.

    Identification of metabolites in human hepatic bile using 800 MHz H-1 NMR spectroscopy, HPLC-NMR/MS and UPLC-MS

    Mol. Biosyst.

    (2009)
  • T. Dyrks et al.

    Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimers-disease

    EMBO J.

    (1988)
  • W.F. Gattaz et al.

    Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease

    Eur. Arch. Psychiatry Clin. Neurosci.

    (1996)
  • M. Gaudin et al.

    Choline-containing phospholipids in microdissected human Alzheimer's disease brain senile plaque versus neuropil

    Bioanalysis

    (2012)
  • Cited by (233)

    • Metabolic profiling of Alzheimer's disease: Untargeted metabolomics analysis of plasma samples

      2023, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    View all citing articles on Scopus
    View full text